Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul-Aug;70(897):57-60.
doi: 10.1016/j.soin.2025.05.020. Epub 2025 Jun 27.

[GLP1 receptor agonist drug treatments and adult obesity]

[Article in French]
Claire Carette  1 , Aurélie Phan  2 , Sébastien Czernichow  2
Affiliations
Free article

[GLP1 receptor agonist drug treatments and adult obesity]

[Article in French]
Claire Carette et al. Soins. 2025 Jul-Aug.
Free article

Abstract

Obesity is a chronic disease with multiple causes and serious complications. Treatments include lifestyle modifications and, for severe cases, medication. Today, molecules such as liraglutide and semaglutide are showing promising results in terms of weight loss and even cardiovascular benefits (for the latter), although reimbursement is limited in France. The dual agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptors (tirzepatide) also offers encouraging prospects. Research is continuing with bi- and tri-agonists to improve the management of obesity.

Keywords: glucagon intestinal peptide; glucagon-like peptide 1; liraglutide; semaglutide; sémaglutide; tirzepatide; tirzépatide.

PubMed Disclaimer

Conflict of interest statement

Déclaration de liens d’intérêts Claire Carette : travaux d’expertise, conférences rémunérées et invitations à des congrès par les laboratoires Boehringer Ingelheim, Pfizer, Bioproject Pharma, Novo Nordisk, AstraZeneca, Novartis, Ipsen, MSD, Eli Lilly et Rhythm. Aurélie Phan : travaux d’expertise, invitations à des congrès par les laboratoires Lilly, Novo Nordisk, Sanofi. Sébastien Czernichow : travaux d’expertise, conférences rémunérées et invitations à des congrès par les laboratoires Lilly, Fresenius, Novartis, Pfizer, Novo Nordisk, BMS, Boehringer, Bariatek. Participation : Mygoodlife, Alifert.

Publication types

MeSH terms

LinkOut - more resources